Page last updated: 2024-11-13
cheliensisin a
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
cheliensisin A: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 56683717 |
| CHEMBL ID | 1818734 |
| SCHEMBL ID | 15937093 |
| MeSH ID | M0490958 |
Synonyms (3)
| Synonym |
|---|
| cheliensisin a |
| CHEMBL1818734 |
| SCHEMBL15937093 |
Research Excerpts
Overview
Cheliensisin A is a natural styryl-lactone isolated from Goniothalamus cheliensis Hu. It has putative anticancer activities.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Cheliensisin A is a natural styryl-lactone isolated from Goniothalamus cheliensis Hu in considerably large quantity with putative anticancer activities. " | ( Development of novel conformation-constrained cytotoxic derivatives of cheliensisin A by embedment of small heterocycles. Deng, X; Li, Y; Peng, LY; Su, J; Yao, ZJ; Zhao, QS; Zhao, Y, 2011) | 2.05 |
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| " However, due to its poor water solubility and chemical instability, choosing the appropriate dosage form is of great significance." | ( Lyophilized Cheliensisin A submicron emulsion for intravenous injection: characterization, in vitro and in vivo antitumor effect. Fu, Y; Gong, T; He, LL; Liu, J; Nie, Y; Zhang, ZR; Zhao, D, 2008) | 0.72 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (6)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID613816 | Cytotoxicity against human A549 cells after 48 hrs by MTT assay | 2011 | European journal of medicinal chemistry, Sep, Volume: 46, Issue:9 | Development of novel conformation-constrained cytotoxic derivatives of cheliensisin A by embedment of small heterocycles. |
| AID613814 | Cytotoxicity against human HL60 cells after 48 hrs by MTT assay | 2011 | European journal of medicinal chemistry, Sep, Volume: 46, Issue:9 | Development of novel conformation-constrained cytotoxic derivatives of cheliensisin A by embedment of small heterocycles. |
| AID613817 | Cytotoxicity against human SKBR3 cells after 48 hrs by MTT assay | 2011 | European journal of medicinal chemistry, Sep, Volume: 46, Issue:9 | Development of novel conformation-constrained cytotoxic derivatives of cheliensisin A by embedment of small heterocycles. |
| AID613818 | Cytotoxicity against human PANC1 cells after 48 hrs by MTT assay | 2011 | European journal of medicinal chemistry, Sep, Volume: 46, Issue:9 | Development of novel conformation-constrained cytotoxic derivatives of cheliensisin A by embedment of small heterocycles. |
| AID613819 | Chemical stability of the compound in 0.1 M phosphate buffer at pH 7.0 at 0.1 mg/mL after 12 hrs by HPLC analysis | 2011 | European journal of medicinal chemistry, Sep, Volume: 46, Issue:9 | Development of novel conformation-constrained cytotoxic derivatives of cheliensisin A by embedment of small heterocycles. |
| AID613815 | Cytotoxicity against human SMMC7721 cells after 48 hrs by MTT assay | 2011 | European journal of medicinal chemistry, Sep, Volume: 46, Issue:9 | Development of novel conformation-constrained cytotoxic derivatives of cheliensisin A by embedment of small heterocycles. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (8)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 6 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.72
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.72) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 8 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||